Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A3ENQ51
Thu, 29.08.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance
Q3 2024 revenues up 21% yoy to EUR 268m at constant currencies
Strong Q3 2024 EBITDA margin of 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first nine month of FY 2024
SCHOTT Pharma increases revenue guidance [ … ]
Thu, 08.08.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
August 8, 2024, Germany, Mainz
SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C.
The independent Science Based Targets initiative (SBTi) has validated the clima [ … ]
Tue, 14.05.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA margin of 27.4% at constant currencies
FY 25 revenue growth projections impacted by lower demand for syringes from one customer
Mid-term outlook confirmed
Full set of Q2 [ … ]
Mon, 18.03.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma to Expand in the U.S. with New Prefillable Syringe Manufacturing Facility in Wilson, North Carolina 18 March 2024, Mainz, Germany
With $371 million investment, new site to add over 400 jobs to the region
First U.S. manufacturing facility to fill demand for domestic supply of glass and polymer prefillable syringes that deliver mRNA, G [ … ]
Thu, 14.03.2024
SCHOTT Pharma AG & Co. KGaA
Successful 2024 Annual General Meeting of SCHOTT Pharma: Shareholders approve all items on the agenda
SCHOTT Pharma's first Annual General Meeting was held virtually on March 14, 2024
Shareholders approved all items on the agenda
SCHOTT Pharma, a pioneer in pharma drug containment solutions and delivery systems, held its first Annual General M [ … ]
Thu, 29.02.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma reports good start into fiscal year 2024
Q1 2024 revenues of EUR 232m; increase of 8% yoy at constant currencies
Q1 2024 EBITDA margin of 27.9% at constant currencies
Share of strong-margin high-value solutions (HVS) further increased to 53%
Guidance for fiscal year 2024 confirmed
SCHOTT Pharma, a pioneer in pharma drug containmen [ … ]
Fri, 26.01.2024
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers on 2023 targets and continues profitable growth trajectory
FY 2023: Revenues up 9% yoy to EUR 899m, EBITDA increase of 9% to EUR 239m, maintaining high EBITDA margin of 26.6%
Strategic shift towards strong-margin high-value solutions (HVS) further accelerated, representing 48% of full year revenues
For FY 2024, SCHOTT Pha [ … ]
Tue, 19.12.2023
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers right after IPO with strong profitable growth for the full year, at the upper end of its guidance
Successful fiscal year 2023, with a year-on-year increase in revenues of 9% to EUR 899m supported by increased share of revenue from strong-margin high-value solutions
Strong EBITDA increase of 9% to EUR 239m leads to an EBITDA [ … ]
Wed, 06.12.2023
SCHOTT Pharma AG & Co. KGaA
Hello SDAX! SCHOTT Pharma reaches next milestone as a publicly listed company
SCHOTT Pharma to join the 160 most important shares listed on the Frankfurt stock exchange as of December 15, 2023
SDAX inclusion underlines company value, business model and strategy
The shares of SCHOTT Pharma AG & Co. KGaA (the “Company”; WKN A3ENQ5, ISIN DE0 [ … ]
Fri, 06.10.2023
SCHOTT Pharma AG & Co. KGaA
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Optio [ … ]